Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 621.71M | 605.22M | 509.34M | 537.84M | 535.03M | 494.37M |
Gross Profit | 479.70M | 468.04M | 381.06M | 422.97M | 420.15M | 387.87M |
EBITDA | -105.45M | -108.26M | -175.87M | -63.11M | -38.38M | 45.30M |
Net Income | -164.19M | -168.63M | -207.04M | -92.53M | -58.35M | 19.81M |
Balance Sheet | ||||||
Total Assets | 370.25M | 1.24B | 1.15B | 1.19B | 1.14B | 1.05B |
Cash, Cash Equivalents and Short-Term Investments | 256.60M | 962.20M | 910.62M | 969.42M | 937.70M | 842.58M |
Total Debt | 160.32M | 683.35M | 596.24M | 584.27M | 575.21M | 444.20M |
Total Liabilities | 243.86M | 880.61M | 783.63M | 750.48M | 729.00M | 575.46M |
Stockholders Equity | 126.39M | 360.18M | 362.50M | 441.17M | 410.49M | 476.53M |
Cash Flow | ||||||
Free Cash Flow | -72.14M | -69.22M | -100.43M | 9.43M | 58.59M | 84.18M |
Operating Cash Flow | -30.46M | -26.37M | -73.34M | 30.79M | 82.76M | 99.15M |
Investing Cash Flow | -392.93M | -140.24M | 184.15M | -139.96M | -144.83M | -472.85M |
Financing Cash Flow | 95.35M | 90.31M | 15.79M | 15.49M | 25.70M | 440.21M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
68 Neutral | $1.55B | ― | -8.38% | ― | 15.79% | -1.20% | |
56 Neutral | $1.04B | ― | -3.29% | ― | -23.12% | 97.46% | |
54 Neutral | $809.26M | 55.81 | -19.14% | ― | -14.44% | -557.38% | |
52 Neutral | $1.90B | ― | -10.59% | ― | -3.18% | 81.18% | |
51 Neutral | $7.36B | 0.28 | -61.07% | 2.37% | 17.46% | 1.71% | |
50 Neutral | $1.86B | ― | -45.52% | ― | 18.27% | 16.28% | |
44 Neutral | $247.26M | ― | -28.58% | ― | 34.65% | -128.56% |
On June 4, 2025, NovoCure held its annual general meeting where shareholders elected eleven directors to serve until the 2026 meeting, with no third-party arrangements involved. Additionally, Francis Leonard was appointed as President of NovoCure and awarded Restricted Share Units under the company’s incentive plan. The meeting also saw the approval of several proposals, including the ratification of the company’s independent auditor, a non-binding advisory vote on executive compensation, and the approval of the 2025 Employee Share Purchase Plan.
The most recent analyst rating on (NVCR) stock is a Hold with a $18.00 price target. To see the full list of analyst forecasts on NovoCure stock, see the NVCR Stock Forecast page.
On May 31, 2025, Novocure announced positive results from its Phase 3 PANOVA-3 clinical trial at the ASCO Annual Meeting, demonstrating that TTFields therapy, when combined with gemcitabine and nab-paclitaxel, significantly improves overall survival and extends pain-free survival for patients with unresectable, locally advanced pancreatic adenocarcinoma. The findings, which will support a Premarket Approval submission to the FDA, highlight TTFields’ potential to become a standard treatment for this challenging cancer type, marking a significant advancement in Novocure’s market positioning and offering hope for improved patient outcomes.
The most recent analyst rating on (NVCR) stock is a Hold with a $18.00 price target. To see the full list of analyst forecasts on NovoCure stock, see the NVCR Stock Forecast page.
On April 22, 2025, Novocure announced that its Optune Lua® device received CE Mark approval for treating adult patients with metastatic non-small cell lung cancer (mNSCLC) in conjunction with immune checkpoint inhibitors or docetaxel, following progression on a platinum-based regimen. This approval, supported by the Phase 3 LUNAR trial, marks a significant milestone for Novocure, as Optune Lua demonstrated a substantial improvement in median overall survival for this patient group, offering a promising new treatment option with minimal systemic toxicity. Novocure is preparing to launch Optune Lua in Germany, following local registration requirements, and will conduct a post-market study to further assess its effectiveness.